Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) has coverage initiated with a Buy rating and $11.00 price target

ME Staff
-
0

Analyst Ratings For Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)

Today, Bank of America initiated coverage on Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) with a Buy with a price target of $11.00.

There are 5 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) is Buy with a consensus target price of $15.25 per share, a potential 271.05% upside.

Some recent analyst ratings include

  • 12/12/2018-Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) has coverage initiated with a Buy rating and $11.00 price target
  • 10/11/2018-Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) has coverage initiated with a Overweight rating
  • 12/14/2017-Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) had its Buy rating reiterated by Guggenheim with a $8.00 price target
  • 7/19/2017-Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) had its Buy rating reiterated by Credit Suisse Group with a $9.00 price target


  • On 12/3/2018 David Domzalski, CEO, sold 68 with an average share price of $4.05 per share and the total transaction amounting to $275.40.
  • On 11/28/2018 Aharon Schwartz, Director, bought 12,200 with an average share price of $3.88 per share and the total transaction amounting to $47,336.00.
  • On 11/26/2018 Aharon Schwartz, Director, bought 50,000 with an average share price of $3.89 per share and the total transaction amounting to $194,500.00.
  • On 11/19/2018 Alvin D Howard, VP, sold 3,375 with an average share price of $3.90 per share and the total transaction amounting to $13,162.50.
  • On 11/19/2018 David Domzalski, CEO, sold 5,036 with an average share price of $3.90 per share and the total transaction amounting to $19,640.40.
  • On 11/8/2018 David Domzalski, CEO, sold 2,062 with an average share price of $4.58 per share and the total transaction amounting to $9,443.96.
  • On 11/8/2018 Iain Stuart, SVP, sold 683 with an average share price of $4.58 per share and the total transaction amounting to $3,128.14.

About Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)
Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular rosacea, and other skin conditions in the United States and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a double-blind and dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus. The company is also developing FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea; and FDX104 that has completed Phase II clinical trial for the treatment of chemotherapy-induced rash. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; Mylan N.V.; and Actavis Laboratories. The company was founded in 2003 and is headquartered in Rehovot, Israel.

Recent Trading Activity for Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)
Shares of Foamix Pharmaceuticals Ltd closed the previous trading session at 4.08 up +0.28 7.22% with 3.96 shares trading hands.